The immunologic state of a patient determines de efficiency of the clinical trials done, making clear the results.

The study of molecular biomarkers and functional trials, need to be standardized validate before they can be routinely implemented in the immunological risk valuation.

Immunoscience gives this service as a complement to the clinical investigation helping in that way to reach its objectives.